Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LEXX Lexaria Bioscience Corp
- Stocks
- Healthcare
- NASDAQ: LEXX
Price (delayed)
$1.07
Market cap
$18.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
$12.44M
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's
Highlights
The gross profit has grown by 35% YoY and by 6% from the previous quarter
LEXX's revenue is up by 30% year-on-year and by 6% since the previous quarter
Lexaria Bioscience's equity has decreased by 27% from the previous quarter but it has increased by 10% YoY
The EPS has declined by 18% since the previous quarter but it rose by 13% year-on-year
The company's quick ratio has shrunk by 94% YoY and by 87% QoQ
The net income has shrunk by 72% YoY and by 28% QoQ
Key stats
What are the main financial stats of LEXX
Market
Valuations
Earnings
Shares outstanding
17.56M
Market cap
$18.79M
Enterprise value
$12.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
35.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.66
Revenue
$525,923
Gross profit
$523,203
Operating income
-$9.39M
Net income
-$9.38M
EBIT
-$9.38M
EBITDA
-$9.28M
Free cash flow
-$7.45M
Per share
Balance sheet
Liquidity
EPS
-$0.59
EPS diluted
-$0.59
Free cash flow per share
-$0.43
Book value per share
$0.41
Revenue per share
$0.03
TBVPS
$0.47
Total assets
$8.68M
Total liabilities
$1.92M
Debt
$123,723
Equity
$7.14M
Working capital
$5.9M
Debt to equity
0.02
Current ratio
4.24
Quick ratio
3.81
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-1,764.3%
Gross margin
99.5%
Net margin
-1,784.2%
Operating margin
-1,785%
Return on assets
-100.5%
Return on equity
-107%
Return on invested capital
-1,258.2%
Return on capital employed
-136.9%
Return on sales
-1,784.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEXX stock price
How has the Lexaria Bioscience stock price performed over time
Intraday
-0.47%
1 week
-0.93%
1 month
-20.74%
1 year
-66.35%
YTD
-49.05%
QTD
-37.43%
Financial performance
How have Lexaria Bioscience's revenue and profit performed over time
Revenue
$525,923
Gross profit
$523,203
Operating income
-$9.39M
Net income
-$9.38M
Gross margin
99.5%
Net margin
-1,784.2%
LEXX's operating income has dropped by 76% year-on-year and by 29% since the previous quarter
The net income has shrunk by 72% YoY and by 28% QoQ
The operating margin has declined by 36% year-on-year and by 21% since the previous quarter
The gross profit has grown by 35% YoY and by 6% from the previous quarter
Price vs fundamentals
How does LEXX's price correlate with its fundamentals
Growth
What is Lexaria Bioscience's growth rate over time
Valuation
What is Lexaria Bioscience stock price valuation
P/E
N/A
P/B
2.63
P/S
35.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.66
The EPS has declined by 18% since the previous quarter but it rose by 13% year-on-year
LEXX's P/B is 47% below its last 4 quarters average of 5.0 and 39% below its 5-year quarterly average of 4.3
Lexaria Bioscience's equity has decreased by 27% from the previous quarter but it has increased by 10% YoY
The stock's price to sales (P/S) is 60% less than its last 4 quarters average of 88.5 and 45% less than its 5-year quarterly average of 65.2
LEXX's revenue is up by 30% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Lexaria Bioscience business performance
The company's return on invested capital has shrunk by 144% YoY and by 79% QoQ
The return on sales has declined by 33% year-on-year and by 21% since the previous quarter
Lexaria Bioscience's ROE has decreased by 26% from the previous quarter but it has increased by 13% YoY
Lexaria Bioscience's ROA has decreased by 20% from the previous quarter but it has increased by 15% YoY
Dividends
What is LEXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEXX.
Financial health
How did Lexaria Bioscience financials performed over time
LEXX's current ratio has dropped by 94% year-on-year and by 86% since the previous quarter
The company's quick ratio has shrunk by 94% YoY and by 87% QoQ
The debt is 98% smaller than the equity
LEXX's debt to equity has soared by 100% QoQ
Lexaria Bioscience's equity has decreased by 27% from the previous quarter but it has increased by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.